Schizophrenia
Conditions
Interventions
Product Name: JNJ-37822681/F002
Pharmaceutical Form: Capsule*
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Sponsors
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ·Male or female between 18 and 65 years of age, inclusive ·Female subjects must meet one of the following: –postmenopausal (for at least 12 months), –Surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy) –abstinent (per investigator’s judgement), –if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], male partner sterilization), before entry, and must agree to continue to use the same method of contraception throughout the study. ·Women of childbearing potential must have a negative serum b human chorionic gonadotropin (b hCG) pregnancy test at screening and admission ·Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug. For men that have been clinically determined to be infertile, this restriction is for 5 days after receiving the last dose of study drug. ·In- or outpatients with schizophrenia stably treated for at least 6 months with antipsychotic monotherapy (£ 200mg/d chlorpromazine equivalent dose) or stable for at least 3 months without drug therapy ·PANSS at screening =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: ·A DSM-IV axis I diagnosis other than schizophrenia ·A DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary) ·Any medical condition that could potentially alter the absorption, metabolism, or excretion of the study medication, such as Crohn’s disease, liver disease, or renal disease ·Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic (including seizures or significant cerebrovascular), renal, hepatic, endocrine, or immunologic diseases ·History of neuroleptic malignant syndrome (NMS) ·Other significant and/or unstable systemic illnesses ·Allergy or hypersensitivity to any known antipsychotic compounds ·Inability to swallow the study medication whole with the aid of water (subjects may not chew, divide, dissolve, or crush the study medication, as this may affect the release profile) ·Exposure to an experimental drug or experimental medical device within 90 days before screening ·Significant risk of suicidal or violent behavior ·Female subjects who are pregnant or breastfeeding ·Alanine aminotransferase or aspartate aminotransferase levels more than 2 times the upper limit of normal ·Other biochemistry, hematology, or urinalysis results that are not within the laboratory’s reference range, and that are deemed by the investigator to be clinically significant ·Use of beta-blockers (if used for any indication other than hypertension and still present at baseline) ·Injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening ·Use of fluoxetine or monoamine oxidase inhibitors within 4 weeks before screening ·Use of all other antidepressants, anticonvulsants, or lithium within 2 weeks before baseline ·Received electroconvulsive therapy within 3 months before screening ·Have been involuntarily committed to psychiatric hospitalization ·Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study ·Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective is to investigate the safety and tolerability of JNJ-37822681 administered as qd or bid following a dose titration in male and female patients with stable schizophrenia.;Secondary Objective: The secondary objectives of this study include: • To investigate the plasma pharmacokinetic (PK) profile of JNJ-37822681 administered as once daily (qd) or twice daily (bid) in male and female patients with stable schizophrenia; • To investigate the effect of JNJ-37822681 on plasma prolactin (PRL) levels.;Primary end point(s): Evaluate the safety, tolerability, and PK of JNJ-37822681 in patients with schizophrenia in the predicted clinical dose range. | — |
Countries
Belgium, Germany, Sweden
Outcome results
None listed